AAAAAA
Results: 26-50/65
Authors:
VREDENBURGH JJ
PETERS WP
ROSNER G
DESOMBRE K
JOHNSTON WW
KAMEL A
WU K
BAST RC
Citation: Jj. Vredenburgh et al., DETECTION OF TUMOR-CELLS IN THE BONE-MARROW OF STAGE-IV BREAST-CANCERPATIENTS RECEIVING HIGH-DOSE CHEMOTHERAPY - THE ROLE OF INDUCTION CHEMOTHERAPY, Bone marrow transplantation, 16(6), 1995, pp. 815-821
Authors:
MURASE T
ANSCHER MS
PETROS WP
PETERS WP
JIRTLE RL
Citation: T. Murase et al., CHANGES IN PLASMA TRANSFORMING GROWTH-FACTOR-BETA IN RESPONSE TO HIGH-DOSE CHEMOTHERAPY FOR STAGE-II BREAST-CANCER - POSSIBLE IMPLICATIONS FOR THE PREVENTION OF HEPATIC VENOOCCLUSIVE DISEASE AND PULMONARY DRUGTOXICITY, Bone marrow transplantation, 15(2), 1995, pp. 173-178
Authors:
ASTLES R
PETROS WP
PETERS WP
SEDOR F
Citation: R. Astles et al., ARTIFACTUAL HYPOGLYCEMIA WITH HEMATOPOIETIC CYTOKINES, Clinical chemistry, 41(6), 1995, pp. 202-202
Authors:
GILBERT CJ
OHLY KV
ROSNER G
PETERS WP
Citation: Cj. Gilbert et al., RANDOMIZED, DOUBLE-BLIND COMPARISON OF A PROCHLORPERAZINE-BASED VERSUS A METOCLOPRAMIDE-BASED ANTIEMETIC REGIMEN IN PATIENTS UNDERGOING AUTOLOGOUS BONE-MARROW TRANSPLANTATION, Cancer, 76(11), 1995, pp. 2330-2337
Authors:
ASTLES JR
PETROS WP
PETERS WP
SEDOR FA
Citation: Jr. Astles et al., ARTIFACTUAL HYPOGLYCEMIA ASSOCIATED WITH HEMATOPOIETIC CYTOKINES, Archives of pathology and laboratory medicine, 119(8), 1995, pp. 713-716
Authors:
RAO KMK
CURRIE MS
COHEN HJ
PETERS WP
Citation: Kmk. Rao et al., ALTERATIONS IN L-SELECTIN EXPRESSION AND ELASTASE ACTIVITY IN NEUTROPHILS FROM PATIENTS RECEIVING GRANULOCYTE-COLONY-STIMULATING FACTOR ALONE OR IN CONJUNCTION WITH HIGH-DOSE CHEMOTHERAPY WITH AUTOLOGOUS BONE-MARROW TRANSPLANTATION, Lymphokine and cytokine research, 13(6), 1994, pp. 383-390
Authors:
GILBERT C
MEISENBERG B
VREDENBURGH J
ROSS M
HUSSEIN A
PERFECT J
PETERS WP
Citation: C. Gilbert et al., SEQUENTIAL PROPHYLACTIC ORAL AND EMPIRIC ONCE-DAILY PARENTERAL ANTIBIOTICS FOR NEUTROPENIA AND FEVER AFTER HIGH-DOSE CHEMOTHERAPY AND AUTOLOGOUS BONE-MARROW SUPPORT, Journal of clinical oncology, 12(5), 1994, pp. 1005-1011
Authors:
GILBERT CJ
PETERS WP
Citation: Cj. Gilbert et Wp. Peters, USE OF PARENTERAL ANTIBIOTICS IN NEUTROPENIC PATIENTS - REPLY, Journal of clinical oncology, 12(11), 1994, pp. 2518-2519
Authors:
ROMP KG
PETERS WP
HOFFMAN M
Citation: Kg. Romp et al., RETICULATED PLATELET COUNTS IN PATIENTS UNDERGOING AUTOLOGOUS BONE-MARROW TRANSPLANTATION - AN AID IN ASSESSING MARROW RECOVERY, American journal of hematology, 46(4), 1994, pp. 319-324
Authors:
PETROS WP
RABINOWITZ J
STUART AR
GUPTON C
ALDERMAN EM
PETERS WP
Citation: Wp. Petros et al., ELEVATED ENDOGENOUS SERUM MACROPHAGE-COLONY-STIMULATING FACTOR IN THEEARLY-STAGE OF FUNGEMIA FOLLOWING BONE-MARROW TRANSPLANTATION, Experimental hematology, 22(7), 1994, pp. 582-586
Authors:
NEMUNAITIS J
ROSS M
MEISENBERG B
APPELBAUM FR
BUHLES W
SINGER J
PETERS WP
OREILLY R
LILLEBY K
BUCKNER CD
Citation: J. Nemunaitis et al., PHASE-I STUDY OF RECOMBINANT HUMAN INTERLEUKIN-1-BETA (RHIL-1-BETA) IN PATIENTS WITH BONE-MARROW FAILURE, Bone marrow transplantation, 14(4), 1994, pp. 583-588
Authors:
MEISENBERG B
LASSITER M
HUSSEIN A
ROSS M
VREDENBURGH JJ
PETERS WP
Citation: B. Meisenberg et al., PREVENTION OF HEMORRHAGIC CYSTITIS AFTER HIGH-DOSE ALKYLATING AGENT CHEMOTHERAPY AND AUTOLOGOUS BONE-MARROW SUPPORT, Bone marrow transplantation, 14(2), 1994, pp. 287-291
Authors:
PETERS WP
ROSS M
VREDENBURGH JJ
HUSSEIN A
RUBIN P
DUKELOW K
CAVANAUGH C
BEAUVAIS R
KASPRZAK S
Citation: Wp. Peters et al., THE USE OF INTENSIVE CLINIC SUPPORT TO PERMIT OUTPATIENT AUTOLOGOUS BONE-MARROW TRANSPLANTATION FOR BREAST-CANCER, Seminars in oncology, 21(4), 1994, pp. 25-31
Authors:
SMYTH AC
BENEAR JB
COLTMAN CA
WINN RJ
BAILES JS
GRECO FA
KELSEN D
ADELSTEIN DJ
KEMENY N
VOSE JM
BOLWELL BJ
NORTON L
PETERS WP
EINHORN LH
SUTTON GP
ALBERTS DS
WALSH D
Citation: Ac. Smyth et al., THE COMMUNITY APPROACH TO SALVAGE THERAPY IN THE TREATMENT OF ADVANCED CANCER - DISCUSSION, Seminars in oncology, 21(4), 1994, pp. 123-132
Authors:
PETERS WP
ROGERS MC
Citation: Wp. Peters et Mc. Rogers, VARIATIONS IN INSURANCE-COVERAGE FOR AUTOLOGOUS BONE-MARROW TRANSPLANTATION FOR BREAST-CANCER - REPLY, The New England journal of medicine, 331(5), 1994, pp. 330-331
Authors:
PETERS WP
ROGERS MC
Citation: Wp. Peters et Mc. Rogers, VARIATION IN APPROVAL BY INSURANCE COMPANIES OF COVERAGE FOR AUTOLOGOUS BONE-MARROW TRANSPLANTATION FOR BREAST-CANCER, The New England journal of medicine, 330(7), 1994, pp. 473-477
Authors:
PETERS WP
Citation: Wp. Peters, CONTRIBUTIONS FROM THE AMERICAN MEDICAL POLITICAL-ACTION COMMITTEE TOMEMBERS OF CONGRESS, The New England journal of medicine, 330(22), 1994, pp. 1615-1615
Authors:
STRAUSS GHS
PETERS WP
EVERSON RB
Citation: Ghs. Strauss et al., MEASURING DNA-DAMAGE IN INDIVIDUAL CELLS OF HETEROGENEOUS MIXTURES - A NOVEL APPLICATION OF AN IMMUNOLOGICAL TYPING TECHNIQUE, MUTATION RESEARCH, 304(2), 1994, pp. 211-216
Authors:
MUDAD R
VREDENBURGH J
PAULSON EK
ROSS M
MEISENBERG B
HUSSEIN A
PETERS WP
Citation: R. Mudad et al., A RADIOLOGIC SYNDROME AFTER HIGH-DOSE CHEMOTHERAPY AND AUTOLOGOUS BONE-MARROW TRANSPLANTATION, WITH CLINICAL AND PATHOLOGICAL FEATURES OF SYSTEMIC CANDIDIASIS, Cancer, 74(4), 1994, pp. 1360-1366
Authors:
MARKS LB
ROSNER GL
PROSNITZ LR
ROSS M
VREDENBURGH JJ
PETERS WP
Citation: Lb. Marks et al., THE IMPACT OF CONVENTIONAL PLUS HIGH-DOSE CHEMOTHERAPY WITH AUTOLOGOUS BONE-MARROW TRANSPLANTATION ON HEMATOLOGIC TOXICITY DURING SUBSEQUENT LOCAL-REGIONAL RADIOTHERAPY FOR BREAST-CANCER, Cancer, 74(11), 1994, pp. 2964-2971
Authors:
VREDENBURGH J
WATERSPICK B
DRAGO S
AFFRONTI ML
KURTZBERG J
ROSS M
HUSSEIN A
RUBIN P
ELKORDY M
MEISENBERG B
PETERS WP
Citation: J. Vredenburgh et al., G-CSF-PRIMED PERIPHERAL-BLOOD PROGENITOR CELLS (PBPCS) COLLECTED IN THE STEADY-STATE ARE SUPERIOR TO G-CSF-PRIMED PBPCS COLLECTED ON THE REBOUND FROM CHEMOTHERAPY, Blood, 84(10), 1994, pp. 10000107-10000107
Authors:
PETROS WP
RABINOWITZ J
RICKS D
STUART A
PETERS WP
Citation: Wp. Petros et al., ELEVATIONS IN MONOCYTE-CHEMOATTRACTANT PROTEIN-1 (MCP-1) CONCENTRATIONS FOLLOWING HIGH-DOSE CHEMOTHERAPY AND AUTOLOGOUS BONE-MARROW SUPPORT, Blood, 84(10), 1994, pp. 10000137-10000137
Authors:
RABINOWITZ J
PETROS WP
REISNER EG
BERRY D
STUART A
PETERS WP
Citation: J. Rabinowitz et al., ANALYSIS OF FACTORS AFFECTING PLATELET TRANSFUSION REQUIREMENTS FOLLOWING HIGH-DOSE CHEMOTHERAPY AND AUTOLOGOUS BONE-MARROW SUPPORT (ABMS), Blood, 84(10), 1994, pp. 10000492-10000492
Authors:
SHPALL EJ
STEMMER SM
HAMI L
FRANKLIN WA
SHAW L
BONNER HS
BEARMAN SI
PETERS WP
BAST RC
MCCULLOCH W
CAPIZZI R
MITCHELL E
SCHEIN PS
JONES RB
Citation: Ej. Shpall et al., AMIFOSTINE (WR-2721) SHORTENS THE ENGRAFTMENT PERIOD OF 4-HYDROPEROXYCYCLOPHOSPHAMIDE-PURGED BONE-MARROW IN BREAST-CANCER PATIENTS RECEIVING HIGH-DOSE CHEMOTHERAPY WITH AUTOLOGOUS BONE-MARROW SUPPORT, Blood, 83(11), 1994, pp. 3132-3137
Authors:
MEISENBERG BR
ROSS M
VREDENBURGH JJ
JONES R
SHPALL EJ
SEIGLER HF
CONIGLIO DM
WU K
PETERS WP
Citation: Br. Meisenberg et al., RANDOMIZED TRIAL OF HIGH-DOSE CHEMOTHERAPY WITH AUTOLOGOUS BONE-MARROW SUPPORT AS ADJUVANT THERAPY FOR HIGH-RISK, MULTI-NODE-POSITIVE MALIGNANT-MELANOMA, Journal of the National Cancer Institute, 85(13), 1993, pp. 1080-1085